Dean&Francis
ISSN 2959-409X

Current Progress and Prospects in Cancer Immunotherapies

Yihe Zheng

Harrow International School, Beijing, China

lucyzheng2019lz@gmail.com

Abstract:

Cancer is still among the leading causes of death around the world and represents a formidable challenge for both researchers and clinicians. Despite the effectiveness in specific contexts of traditional modalities of treatment, including surgery, radiation, and chemotherapy, they generally lack specificity and long-term efficacy. Currently, immunotherapy has dramatically reshaped the landscape of cancer treatment, providing new hope both for patients and health caregivers. It utilizes the body in the recognition and battle of cancer cells through the use of the immune system, hence offering better-targeted and durable responses. Assorted approaches include checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines have shown promising development and together reflect a shift toward personalized medicine in oncology. This review outlines recent advances in cancer immunotherapies, including breakthroughs and ongoing research, and the challenges remaining for further improvements in patient outcomes and effective cancer treatment. The topic of mechanisms, successes, and future directions concerning these therapies will form the bedrock upon which our assertion stands: the full potential for immunotherapy to revolutionize the paradigm of care in cancer.

Keywords: Cancer; immunotherapies; CAR-T; immune checkpoint inhibitor; vaccine.

1. Introduction

Cancer remains one of the leading causes of morbidity and mortality worldwide, presenting significant challenges for healthcare systems and researchers alike. Traditional treatment modalities—including surgery, chemotherapy, and radiation—have demonstrated effectiveness in various contexts but often come with limitations such as limited specificity, significant side effects, and challenges related to treatment resistance. Immunotherapy has revolutionized cancer treatment in recent years by leveraging the body‘s own immune system to detect and destroy malignant cells [1,2].

Immunotherapies encompass a diverse array of strategies, including immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and cancer vaccines, each designed to enhance the body’s immune response to tumors. Furthermore, these innovative therapies demonstrate a growing under-

ISSN 2959-409X

standing of the complex interactions between the immune system and tumor biology. Using immunotherapy, tumors use specific mechanisms to avoid recognition by the immune system, which helps the immune system identify and eradicate cancer cells.

2. Current Progress in Cancer Immunotherapies

2.1 T Cells

T Cells are a very crucial part of our body's immune system, they are a specific type of White Blood Cells (or leukocytes) called "lymphocytes". Lymphocytes originate from a blood stem cell, where within a process, they gradually develop into a lymphoid stem cell, then into a lymphoblast, and eventually into a T Cell or other types of lymphocytes. T Cells are also commonly known as "T-lymphocytes" or "thymocytes". T Cells originates from our bone marrow, develops within our thymus and finally locates itself within our lymph tissues or blood stream. The most prominent role of T-lymphocytes is that they support our immune system to fight against intruders such as viruses, bacteria or other antigens; protecting our body from harm. Our T cells protect us and eliminate damaging pathogens; detects them, and signals our immune system to fight against them. They can also help fight against cancer cells and as well as infections within our system.

T Cells are essential keystones of our body's adaptive immune system, where our cells work collaboratively against pathogens with a specific and customized strategy based on what they're dealing with. Every T Cell inside our body is unique and is designed for a specific type of sickness, once our body detects any threats, they will then activate the immune system and signal the special type of T Cell to quickly make copies of and defeat the pathogen. Once the pathogen is eliminated, a portion of our effector T Cells becomes memory T Cells, carving a record of this type of intruder; they will be protecting us from future re-infections from the same type of pathogen, but this time our body remembers from its past battles with the support of our helper T Cells, and therefore will be able to defeat them more effectively [3].

There are two major types of T Cells: Cytotoxic T Cells and Helper T Cells. Cytotoxic T Cells have a CD8+ receptor attached to its outer cell membrane; this allows them to eliminate pathogen-inflicted cells, such as cells infected by funguses, bacterias or even tumorous cancer cells. On the other hand, Helper T Cells, instead of CD8+ receptors, they have CD4+ receptors on their membranes. This makes them little helpers of our body's immune system, as they coordinate and signal other factions of our immune system once they locate pathogens, and call for an attack against them. Although, to prevent our T Cells from going too relentless during this battle, another sub-group called regulatory T Cells help to reduce and maintain a balance of the main two types of T Cells. This avoids them harming healthy cells within our system [4].

Depending on the immunological context, T cells can acquire functional and effector phenotypes whose activity has direct inflammatory or anti-inflammatory consequences. During early stages of tumor development, pre-mature T Cells within the lymph node will be activated to reproduce itself due to the immune response. They will be signaled to destroy immunogenic cancer cells. One of the most effective anti-tumor cells are cytotoxic (CD8+) T Cell. Along with the support of Helper (CD4+) T Cells, which signals significant amounts of proinflammatory cytokines such as IL-2, TNF-α, and IFN-γ, this centers and gathers together the anti-tumoral response of our immune system [5,6].

2.2 B Cells

B cells are a type of lymphocyte that form part of the adaptive immune system. These cells primarily act via the synthesis of antibodies to neutralize the pathogen or infectious agents such as bacteria and viruses. Besides their conventional function in immune responses, B cells play critical roles in the biology of tumors. Following activation by antigen, B cells undergo clonal expansion and terminal differentiation into plasma cells that synthesize and secrete large quantities of antibody [7]. The antibodies bind to antigens, either inactivating them directly or flagging them for elimination by other immune cells. Some B cells generated in response to infection differentiate into long-lived memory B cells that can provide a rapid, high-amplitude response upon re encounter with antigen-a hallmark of successful vaccination. Like all antigen-presenting cells, B cells engulf antigens via their surface-bound immunoglobulins, process them, and then display the antigen fragments together with MHC class II molecules to helper T cells [8]. This interaction is very important to T cell activation and orchestrating a more robust immune response. B cells have the ability to manufacture a variety of cytokines that would modulate immune responses and may make a balance between different kinds of immune reactions, such as Th1/Th2 responses [9]. B cells may have both positive and negative roles within tumor contexts. In some types of cancer, B cells promote tumor development. Sometimes the tumor microenvironment can lead to the activation and survival of B cells capable of producing antibodies that promote tumor

growth, angiogenesis, and immune evasion. In this condition, B cells in solid tumors generally present in positive clinical prognosis in various cancers. B cells infiltrating in tumors can produce tumor antigen-specific antibodies, which contribute to antitumor immune responses [10,11].

3. Immunotherapies in Cancer

3.1 Cancer Vaccines

There are two main types of cancer vaccines: preventive (or prophylactic) and therapeutic (or treatment) vaccines. Preventive vaccines aim to prevent cancer from developing in healthy individuals by targeting cancer-associated viruses or precancerous conditions.

Cancer vaccines target specific antigens that are overexpressed or uniquely expressed on cancer cells. These antigens can be derived from tumor-associated proteins, mutated proteins, or cancer cell-specific antigens. The vaccine introduces these antigens into the body along with adjuvants, which are substances that enhance the immune response. This prompts the immune system to recognize the antigens as threats and to mount a defense [12]. The introduction of antigens stimulates the activation of T-cells, which are critical components of the immune system. Activated T-cells specifically target and destroy cancer cells presenting the antigens. Ideally, the immune system develops a memory of the cancer antigens, allowing it to recognize and attack cancer cells more effectively if they reappear in the future.

Preventive Cancer Vaccines, the most notable example is the HPV vaccine, which has significantly reduced the incidence of cervical cancer and other HPV-related cancers. Similarly, the hepatitis B vaccine helps prevent liver cancer by targeting the hepatitis B virus, which is a major risk factor for liver cancer. Several therapeutic cancer vaccines are in clinical use or development. One of the most well-known examples is the prostate cancer vaccine Provenge (sipuleucel-T). Provence is used to treat advanced prostate cancer and works by stimulating an immune response against prostate cancer cells. Another example is the melanoma vaccine, which targets melanoma-associated antigens to treat patients with metastatic melanoma. Personalized Cancer Vaccines has shown a great potential in the treatment of cancer. Advances in genomic and proteomic technologies are leading to the development of personalized cancer vaccines [13]. These vaccines are tailored to the unique genetic mutations present in an individual's tumor. By targeting these specific mutations, personalized vaccines aim to enhance the effectiveness of treatment and minimize off-target effects. Combining cancer vaccines with other treatments, such as checkpoint inhibitors or targeted therapies, is an emerging strategy. This approach leverages the strengths of different therapies to overcome resistance mechanisms and improve overall efficacy.

3.2 Cytokine Therapies

Cytokine therapies represent a significant advancement in cancer treatment, leveraging the body's own signaling molecules to enhance the immune response against tumors. Cytokines are small proteins that facilitate communication between cells and play crucial roles in regulating immune responses. This essay explores the mechanisms behind cytokine therapies and their applications in cancer treatment.

Interleukins (ILs), Interleukins are a group of cytokines that promote the growth, differentiation, and activation of immune cells. For instance, Interleukin-2 (IL-2) is a key cytokine used in cancer therapy. IL-2 stimulates the proliferation of T-cells, including cytotoxic T lymphocytes (CTLs), which are crucial for targeting and destroying cancer cells. IL-2 also enhances the activity of natural killer (NK) cells and promotes the generation of memory T-cells, which provide long-term immunity against cancer [3]. IL-2 Therapy, High-dose IL-2 therapy has shown significant efficacy in treating metastatic melanoma and renal cell carcinoma. It can lead to durable responses and, in some cases, complete remission. However, the high-dose regimen is associated with severe side effects, such as flu-like symptoms, hypotension, and organ toxicity, which limits its use to carefully selected patients.

Interferons (IFNs) are cytokines that exhibit antiviral, antiproliferative, and immunomodulatory effects. Interferon-alpha (IFN-α) has been used to treat various cancers, including melanoma and renal cell carcinoma. IFN-α enhances the immune system's ability to recognize cancer cells by increasing the expression of major histocompatibility complex (MHC) molecules on tumor cells. This makes it easier for T-cells to identify and attack the cancer. Interferons also have direct antiproliferative effects on tumor cells, inhibiting their growth and division. IFN-α has been used to treat several cancers, including melanoma, renal cell carcinoma, and chronic myelogenous leukemia (CML). It has demonstrated efficacy in inducing remission and prolonging survival in some patients. IFN-α therapy is often associated with side effects such as flu-like symptoms, fatigue, and depression, which can affect patient compliance [14].

Tumor Necrosis Factor (TNF), TNF is a cytokine with potent antitumor effects. TNF-α, in particular, can induce apoptosis (programmed cell death) in tumor cells and enhance the immune system's ability to target cancer. TNF-α can also increase the permeability of blood ves-

ISSN 2959-409X

sels in tumors, allowing immune cells and therapeutic agents to penetrate and attack the cancer more effectively. However, the systemic use of TNF-α can be associated with significant side effects, limiting its application. TNF therapy has been investigated in clinical trials for its potential to treat various cancers, including sarcoma and melanoma. While it has shown promise in preclinical studies, its clinical application has been limited by the risk of severe adverse effects, such as fever, hypotension, and organ damage.GM-CSF Therapy-CSF has been used in combination with cancer vaccines to enhance their effectiveness. For example, GM-CSF was used in conjunction with the melanoma vaccine to improve immune responses and clinical outcomes. Additionally, GM-CSF is used to support patients undergoing chemotherapy by stimulating the production of white blood cells and reducing the risk of infection.

Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF),GM-CSF is a cytokine that stimulates the production and activation of white blood cells, including macrophages and dendritic cells. By boosting the number and activity of these immune cells, GM-CSF can enhance the body's immune response against cancer. GM-CSF has been used in combination with cancer vaccines to improve their efficacy by promoting a more robust immune response.

Despite their potential, cytokine therapies face several challenges. The systemic administration of cytokines can lead to significant side effects, including cytokine release syndrome, which can be life-threatening. Furthermore, the efficacy of cytokine therapies can be limited by the heterogeneous nature of tumors and the variability in individual patient responses.

3.3 Adoptive Cell Transfer

The first step in ACT is the collection of immune cells, typically T-cells, from the patient‘s blood. This is usually done through a procedure called leukapheresis, where white blood cells are separated from other blood components and collected for further processing. Once collected, the T-cells are isolated and activated in the laboratory. In some cases, these cells are genetically modified to enhance their cancer-fighting capabilities. This can involve the introduction of chimeric antigen receptors (CARs) or tumor-infiltrating lymphocytes (TILs). CAR-T cell therapy, a prominent form of ACT, involves engineering T-cells to express receptors that specifically target cancer cell antigens. TIL therapy, another form, involves expanding T-cells that have naturally infiltrated the tumor, selecting those with the highest anti-tumor activity. After modification and expansion, the engineered or selected T-cells are infused back into the patient's body. The reintroduced cells then seek out and attack cancer cells. This step is often preceded by a preparative regimen, such as chemotherapy or radiation, to create a more favorable environment for the infused cells by reducing the number of competing immune cells and making space for the new cells to thrive. Monitoring and Support, Post-infusion, patients are closely monitored for responses and potential side effects. The infused T-cells can persist in the body for extended periods, continuing to target cancer cells and potentially provide long-term protection against relapse.

CAR-T cell therapy has achieved remarkable success in treating hematologic malignancies such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). In CAR-T cell therapy, T-cells are engineered to express synthetic receptors that recognize specific cancer cell antigens, such as CD19 in B-cell malignancies. The FDA has approved several CAR-T therapies, including Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel), which have demonstrated high remission rates in patients with otherwise refractory or relapsed cancers. Tumor-infiltrating lymphocyte therapy has shown efficacy in treating solid tumors, particularly melanoma. In TIL therapy, T-cells are harvested from a patient's tumor, expanded ex vivo, and reinfused. The expanded TILs have demonstrated the ability to recognize and attack tumor cells more effectively. Clinical trials have reported encouraging results in patients with advanced melanoma, with some achieving durable responses and long-term remission [15].

Genetic engineering, advances in genetic engineering have led to the development of next-generation ACT approaches. Researchers are exploring strategies such as dual-target CAR-T cells, which can recognize two different antigens on cancer cells, and "off-the-shelf" CAR-T cells derived from healthy donors. These innovations aim to enhance the efficacy of ACT and broaden its applicability to a wider range of cancers.

3.4 Immune Checkpoint Inhibitors

Programmed Cell Death Protein 1 (PD-1) and its ligand PD-L1, PD-1 is a receptor found on the surface of T-cells, and its primary function is to downregulate immune responses and prevent autoimmunity [16]. When PD-1 binds to its ligands, PD-L1 or PD-L2, which are often expressed on tumor cells, it sends an inhibitory signal to T-cells, reducing their ability to attack cancer cells. Immune checkpoint inhibitors targeting PD-1 (such as pembrolizumab and nivolumab) or PD-L1 (such as atezolizumab and durvalumab) block this interaction, thereby reinvigorating T-cells and enhancing their ability to target and kill tumor

cells [17].

Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4),CTLA-4 is another immune checkpoint protein that acts as a brake on T-cell activation. It competes with the stimulatory receptor CD28 for binding to co-stimulatory molecules on antigen-presenting cells. By binding to these molecules, CTLA-4 inhibits T-cell activation and proliferation. Immune checkpoint inhibitors targeting CTLA-4 (such as ipilimumab) block this interaction, enhancing T-cell activation and boosting the immune response against tumors[8].

Immune checkpoint inhibitors have been particularly successful in treating advanced melanoma, a type of skin cancer. Pembrolizumab and nivolumab, which target PD-1, and ipilimumab, which targets CTLA-4, have been shown to induce significant tumor regression and improve survival rates. The combination of nivolumab and ipilimumab has also demonstrated superior efficacy compared to monotherapy in clinical trials. Non-Small Cell Lung Cancer (NSCLC),Immune checkpoint inhibitors have revolutionized the treatment of NSCLC, the most common type of lung cancer. Pembrolizumab and atezolizumab, which target PD-1 and PD-L1, respectively, have been approved for the treatment of advanced NSCLC, offering significant benefits in terms of progression-free survival and overall survival. These therapies are often used in combination with chemotherapy to enhance their effectiveness.

Atezolizumab, durvalumab, and nivolumab have been approved for the treatment of advanced bladder cancer. These inhibitors work by targeting PD-L1 and PD-1, improving outcomes for patients with metastatic bladder cancer who have not responded to traditional therapies. Hodgkin Lymphoma, Pembrolizumab and nivolumab have shown remarkable efficacy in treating Hodgkin lymphoma, a type of blood cancer. These drugs target PD-1 and have led to high response rates in patients with relapsed or refractory disease [18].

4. Conclusion

With the evolution of immunotherapies, the treatment landscape has been transformed dramatically, with a focus on enhancing the body‘s immune system against cancer. T cell and B cell therapies, cancer vaccines, cytokine therapies, and cell adoptive transfer techniques like CAR-T cell therapy are merely examples of advances in personalized and effective therapies. Each of these approaches uses unique mechanisms to amplify the immune response to tumor cells, which result in improved patients‘ outcomes and, in some instances, even complete remissions in previously refractory cancers. Although these results are promising, there is still a long way to go. Potential adverse effects, variability in patient responses, and complexity of tumor microenvironments will pose major hurdles for the future. As the field continues to evolve, surmounting such challenges through continued research, innovation, and combination therapies will be instrumental in furthering efforts toward optimizing the efficacy and accessibility of immunotherapy. It is also possible that the incorporation of personalized medicine, in which therapies will be targeted to one‘s specific genetic profile and the characteristics of the tumor, will further accelerate that success. As the medical community refines therapeutic strategies and investigates new avenues for treating this disease, present therapies are constantly being improved and new avenues are being explored.

References

[1] Abreu, R. T., Fonseca, A. N., Gonçalves, N., et al. Current challenges and emerging opportunities of CAR-T cell therapies. Journal of Controlled Release, 2020, 319, 246-261.

[2] Balbi, M., Mazzaschi, G., Leo, L., et al. Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors. Journal of Thoracic Imaging, 2024.

[3] Cleveland Clinic. (n.d.). T cells: What they are and how they work. Retrieved September 11, 2024, from https://my.clevelandclinic.org/health/body/24630-t-cells

[4] E M E V, J S S, P J M W, et al. Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer. Journal for Immunotherapy of Cancer, 2023, 11(11).

[5] News-Medical.Net. (2020). What are T Cells? Retrieved September 11, 2024, from https://www.news-medical.net/health/What-are-T-Cells.aspx

[6] Rafi, G. (2016). The role of T cells in immunity and disease. PubMed. https://pubmed.ncbi.nlm.nih.gov/27526640/

[7] Chen, Y., & Liao, T. (2022). The role of B cells in cancer immunoediting: Implications for immunotherapy. Cancer Immunology, Immunotherapy, 71(3), 439-455.

[8] De Silva, N. S., & Klein, U. (2015). Dynamics of B cells in germinal centers. Nature Reviews Immunology, 15(3), 143-155.

[9] Prizant, H., et al. (2016). The role of B cells in cancer immunotherapy. Nature Reviews Cancer, 16(11), 724-740.

[10] Shalabi, H., et al. (2018). B cells and their clinical relevance in oncology. Frontiers in Immunology, 9, 998.

[11] Yao, X., & Wang, D. (2017). B cell responses: From basic biology to immune modulation in disease. Nature Reviews Immunology, 17(5), 267-267. https://doi.org/10.1038/nri.2016.80

[12] Sprooten, J., & Garg, D. A. Next-generation DC vaccines with an immunogenic trajectory against cancer: therapeutic opportunities vs. resistance mechanisms. Genes & Immunity,

ISSN 2959-409X

2024, (prepublish), 1-3.
[13] Zhang, M., Zhao, Y., Lv, B., et al. Engineered Carrier-Free Nanosystem-Induced In Situ Therapeutic Vaccines for Potent Cancer Immunotherapy.
[14]Stanilov, N., Velikova, T., Stanilova, S. Navigating the Cytokine Seas: Targeting Cytokine Signaling Pathways in Cancer Therapy. International Journal of Molecular Sciences, 2024, 25(2).
[15] Kakimi, K., Matsushita, H., Masuzawa, K., et al. Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study. Journal for ImmunoTherapy of Cancer, 2020, 8(2).
[16] Kashimura, S., Sato, M., Inagaki, T., et al. Relationship between the combination of platelet count and neutrophil-lymphocyte ratio and prognosis of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective cohort study. Thoracic Cancer, 2024.
[17] Mazzaschi, G., et al. (2024). Longitudinal changes of CT-radiomic and systemic inflammatory features predict survival in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors. Journal of Thoracic Imaging.
[18] National Cancer Institute. (n.d.). T cell. In Dictionary of Cancer Terms. Retrieved September 11, 2024, from https://www.cancer.gov/publications/dictionaries/cancer-terms/def/t-cell